chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood test, Dizziness, Dysstasia, Nausea, Syncope
Clinical narrative: fainted and was taken to the emergency department; Severe Dizziness and nausea minutes after vaccine; Severe Dizziness and nausea minutes after vaccine; This is a spontaneous report from a contactable consumer. A 32-year-old female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) lot number: EP6955, via an unspecified route of administration, administered in left arm on 19Mar2021 12:30 as single dose for Covid-19 immunisation. Medical history included temporomandibular joint syndrome and anxiety. Concomitant medication included vortioxetine hydrobromide (TRINTELLIX) and buspirone. The patient previously took tetracycline and experienced allergic reaction. On 19Mar2021, the patient experienced severe dizziness and nausea minutes after vaccine. The patient fainted and was taken to the emergency department. The patient received Benadryl, steroids, IV fluids and nausea medication. The outcome of the events was not recovered.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dizziness, Nausea, Syncope
Clinical narrative: fainted and was taken to the emergency department; Severe Dizziness and nausea minutes after vaccine; Severe Dizziness and nausea minutes after vaccine; This is a spontaneous report from a contactable consumer. A 32-year-old female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) lot number: EP6955, via an unspecified route of administration, administered in left arm on 19Mar2021 12:30 as single dose for Covid-19 immunisation. Medical history included temporomandibular joint syndrome and anxiety. Concomitant medication included vortioxetine hydrobromide (TRINTELLIX) and buspirone. The patient previously took tetracycline and experienced allergic reaction. On 19Mar2021, the patient experienced severe dizziness and nausea minutes after vaccine. The patient fainted and was taken to the emergency department. The patient received Benadryl, steroids, IV fluids and nausea medication. The outcome of the events was not recovered.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dizziness, Loss of consciousness, Malaise, Nausea, Pain
Clinical narrative: fainted and was taken to the emergency department; Severe Dizziness and nausea minutes after vaccine; Severe Dizziness and nausea minutes after vaccine; This is a spontaneous report from a contactable consumer. A 32-year-old female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) lot number: EP6955, via an unspecified route of administration, administered in left arm on 19Mar2021 12:30 as single dose for Covid-19 immunisation. Medical history included temporomandibular joint syndrome and anxiety. Concomitant medication included vortioxetine hydrobromide (TRINTELLIX) and buspirone. The patient previously took tetracycline and experienced allergic reaction. On 19Mar2021, the patient experienced severe dizziness and nausea minutes after vaccine. The patient fainted and was taken to the emergency department. The patient received Benadryl, steroids, IV fluids and nausea medication. The outcome of the events was not recovered.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Alanine aminotransferase increased, Aspartate aminotransferase increased, Cholecystectomy, Endoscopic retrograde cholangiopancreatography, Lipase increased
Clinical narrative: Labs showed a lipase over 2800; Vomiting; Gallbladder pancreatitis; Gallstones; This is a spontaneous report from a contactable consumer (patient). A 20-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EN6199), via an unspecified route of administration, administered in right arm on 11Mar2021 as single dose for COVID-19 immunization. Medical history included nausea from 10Mar2021 to 12Mar2021. Concomitant medication includes ethinylestradiol, norethisterone acetate (JUNEL FE 1/20) taken for contraception. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient experienced vomiting on 13Mar2021 in the morning and continued until 14Mar2021 in the morning. The patient went to Urgent Care on 14Mar2021 in the morning where labs were completed. Labs showed a lipase over 2800 on 14Mar2021 and was instructed to go to the emergency room (ER). She went to the ER on 14Mar2021 around 7 PM and was admitted around midnight. It was deducted as gallbladder pancreatitis. The patient had an ERCP procedure on 15Mar2021 afternoon to remove gallstones. Her gallbladder was also removed in the morning of 16Mar2021. The patient was released 16Mar2021 evening from the hospital. It was reported that the events resulted in Emergency room/department or urgent care. Treatment received for the adverse events included ERCP and Gallbladder Removal Surgery. Since the vaccination, the patient has been tested for COVID-19 (unknown date and result); and on 14Mar2021, the patient underwent nasal swab with negative result. The outcome of the event vomiting was recovered on 14Mar2021, and unknown for other events.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Nausea, Obstructive pancreatitis, Vomiting
Clinical narrative: Labs showed a lipase over 2800; Vomiting; Gallbladder pancreatitis; Gallstones; This is a spontaneous report from a contactable consumer (patient). A 20-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EN6199), via an unspecified route of administration, administered in right arm on 11Mar2021 as single dose for COVID-19 immunization. Medical history included nausea from 10Mar2021 to 12Mar2021. Concomitant medication includes ethinylestradiol, norethisterone acetate (JUNEL FE 1/20) taken for contraception. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient experienced vomiting on 13Mar2021 in the morning and continued until 14Mar2021 in the morning. The patient went to Urgent Care on 14Mar2021 in the morning where labs were completed. Labs showed a lipase over 2800 on 14Mar2021 and was instructed to go to the emergency room (ER). She went to the ER on 14Mar2021 around 7 PM and was admitted around midnight. It was deducted as gallbladder pancreatitis. The patient had an ERCP procedure on 15Mar2021 afternoon to remove gallstones. Her gallbladder was also removed in the morning of 16Mar2021. The patient was released 16Mar2021 evening from the hospital. It was reported that the events resulted in Emergency room/department or urgent care. Treatment received for the adverse events included ERCP and Gallbladder Removal Surgery. Since the vaccination, the patient has been tested for COVID-19 (unknown date and result); and on 14Mar2021, the patient underwent nasal swab with negative result. The outcome of the event vomiting was recovered on 14Mar2021, and unknown for other events.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cholelithiasis, Lipase, Lipase increased, Pancreatitis, SARS-CoV-2 test
Clinical narrative: Labs showed a lipase over 2800; Vomiting; Gallbladder pancreatitis; Gallstones; This is a spontaneous report from a contactable consumer (patient). A 20-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EN6199), via an unspecified route of administration, administered in right arm on 11Mar2021 as single dose for COVID-19 immunization. Medical history included nausea from 10Mar2021 to 12Mar2021. Concomitant medication includes ethinylestradiol, norethisterone acetate (JUNEL FE 1/20) taken for contraception. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient experienced vomiting on 13Mar2021 in the morning and continued until 14Mar2021 in the morning. The patient went to Urgent Care on 14Mar2021 in the morning where labs were completed. Labs showed a lipase over 2800 on 14Mar2021 and was instructed to go to the emergency room (ER). She went to the ER on 14Mar2021 around 7 PM and was admitted around midnight. It was deducted as gallbladder pancreatitis. The patient had an ERCP procedure on 15Mar2021 afternoon to remove gallstones. Her gallbladder was also removed in the morning of 16Mar2021. The patient was released 16Mar2021 evening from the hospital. It was reported that the events resulted in Emergency room/department or urgent care. Treatment received for the adverse events included ERCP and Gallbladder Removal Surgery. Since the vaccination, the patient has been tested for COVID-19 (unknown date and result); and on 14Mar2021, the patient underwent nasal swab with negative result. The outcome of the event vomiting was recovered on 14Mar2021, and unknown for other events.
Age: 20.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vomiting
Clinical narrative: Labs showed a lipase over 2800; Vomiting; Gallbladder pancreatitis; Gallstones; This is a spontaneous report from a contactable consumer (patient). A 20-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EN6199), via an unspecified route of administration, administered in right arm on 11Mar2021 as single dose for COVID-19 immunization. Medical history included nausea from 10Mar2021 to 12Mar2021. Concomitant medication includes ethinylestradiol, norethisterone acetate (JUNEL FE 1/20) taken for contraception. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient experienced vomiting on 13Mar2021 in the morning and continued until 14Mar2021 in the morning. The patient went to Urgent Care on 14Mar2021 in the morning where labs were completed. Labs showed a lipase over 2800 on 14Mar2021 and was instructed to go to the emergency room (ER). She went to the ER on 14Mar2021 around 7 PM and was admitted around midnight. It was deducted as gallbladder pancreatitis. The patient had an ERCP procedure on 15Mar2021 afternoon to remove gallstones. Her gallbladder was also removed in the morning of 16Mar2021. The patient was released 16Mar2021 evening from the hospital. It was reported that the events resulted in Emergency room/department or urgent care. Treatment received for the adverse events included ERCP and Gallbladder Removal Surgery. Since the vaccination, the patient has been tested for COVID-19 (unknown date and result); and on 14Mar2021, the patient underwent nasal swab with negative result. The outcome of the event vomiting was recovered on 14Mar2021, and unknown for other events.
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Headache, Loss of consciousness, Speech disorder, Syncope
Clinical narrative: patient fainted as lost consciousness; patient fainted as lost consciousness; patient urinated in her pants; Felt dizzy after 12 hours; patient had problems with concentrating; massive headache; This is a spontaneous report from a contactable consumer (patient). A 46-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 09Mar2021 09:30 (lot number: 1; pending clarification) at the age of 46 years old, as single dose for covid-19 immunization. Medical history included allergy to metals (titanium metal). Concomitant medications were none. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No other medications received within 2 weeks of vaccination. The patient was not pregnant at the time of vaccination. The patient was not diagnosed with COVID-19 prior to vaccination. On 09Mar2021 21:00, the patient experienced massive headache. After 12 hours (09Mar2021 21:30), the patient felt dizzy. On 10Mar2021, around 10 am, the patient fainted as lost consciousness, urinated in her pants and had problems with concentrating. No treatment was given for the adverse events. Since vaccination, the patient has not been tested for COVID-19. The patient was recovering from all the events.
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Urinary incontinence
Clinical narrative: patient fainted as lost consciousness; patient fainted as lost consciousness; patient urinated in her pants; Felt dizzy after 12 hours; patient had problems with concentrating; massive headache; This is a spontaneous report from a contactable consumer (patient). A 46-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 09Mar2021 09:30 (lot number: 1; pending clarification) at the age of 46 years old, as single dose for covid-19 immunization. Medical history included allergy to metals (titanium metal). Concomitant medications were none. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No other medications received within 2 weeks of vaccination. The patient was not pregnant at the time of vaccination. The patient was not diagnosed with COVID-19 prior to vaccination. On 09Mar2021 21:00, the patient experienced massive headache. After 12 hours (09Mar2021 21:30), the patient felt dizzy. On 10Mar2021, around 10 am, the patient fainted as lost consciousness, urinated in her pants and had problems with concentrating. No treatment was given for the adverse events. Since vaccination, the patient has not been tested for COVID-19. The patient was recovering from all the events.
Age: 46.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Disturbance in attention, Dizziness, Headache, Loss of consciousness, Syncope
Clinical narrative: patient fainted as lost consciousness; patient fainted as lost consciousness; patient urinated in her pants; Felt dizzy after 12 hours; patient had problems with concentrating; massive headache; This is a spontaneous report from a contactable consumer (patient). A 46-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 09Mar2021 09:30 (lot number: 1; pending clarification) at the age of 46 years old, as single dose for covid-19 immunization. Medical history included allergy to metals (titanium metal). Concomitant medications were none. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No other medications received within 2 weeks of vaccination. The patient was not pregnant at the time of vaccination. The patient was not diagnosed with COVID-19 prior to vaccination. On 09Mar2021 21:00, the patient experienced massive headache. After 12 hours (09Mar2021 21:30), the patient felt dizzy. On 10Mar2021, around 10 am, the patient fainted as lost consciousness, urinated in her pants and had problems with concentrating. No treatment was given for the adverse events. Since vaccination, the patient has not been tested for COVID-19. The patient was recovering from all the events.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Alice in wonderland syndrome, Dizziness, Feeling abnormal, Headache, Hyperacusis
Clinical narrative: WHOLE FACE NUMBNESS; SPEECH ISSUE; EYE LIDS SAGGY; VISUAL DISTORTION; ALL LIMBS WEAKNESS; FEVER; HEADACHE; DRAGGING FEET WHEN WALKING; This spontaneous report received from a patient concerned a 48 year old female. The patient's weight was 155 pounds, and height was 158 inches. The patient's concurrent conditions included TODD syndrome -alice in wonderland syndrome, and allergic to clarithromycin. The patient had no history of drug abuse or illicit drug use. The patient was not pregnant at the time of reporting. The patient was non-smoker and non-alcohol user. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022, expiry: UNKNOWN) dose was not reported, administered on 15-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, the subject experienced dragging feet when walking. On 16-MAR-2021, the subject experienced headache. On 17-MAR-2021, the subject experienced visual distortion. On 17-MAR-2021, the subject experienced all limbs weakness. On 17-MAR-2021, the subject experienced fever. On 23-MAR-2021, the subject experienced eye lids saggy. On 26-MAR-2021, the subject experienced whole face numbness. On 26-MAR-2021, the subject experienced speech issue. Treatment medications (dates unspecified) included: naproxen, and ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on MAR-2021, had not recovered from whole face numbness, and the outcome of headache, all limbs weakness, eye lids saggy, speech issue, visual distortion and dragging feet when walking was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hyperhidrosis, Limb discomfort, Malaise, Nausea, Pain
Clinical narrative: WHOLE FACE NUMBNESS; SPEECH ISSUE; EYE LIDS SAGGY; VISUAL DISTORTION; ALL LIMBS WEAKNESS; FEVER; HEADACHE; DRAGGING FEET WHEN WALKING; This spontaneous report received from a patient concerned a 48 year old female. The patient's weight was 155 pounds, and height was 158 inches. The patient's concurrent conditions included TODD syndrome -alice in wonderland syndrome, and allergic to clarithromycin. The patient had no history of drug abuse or illicit drug use. The patient was not pregnant at the time of reporting. The patient was non-smoker and non-alcohol user. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022, expiry: UNKNOWN) dose was not reported, administered on 15-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, the subject experienced dragging feet when walking. On 16-MAR-2021, the subject experienced headache. On 17-MAR-2021, the subject experienced visual distortion. On 17-MAR-2021, the subject experienced all limbs weakness. On 17-MAR-2021, the subject experienced fever. On 23-MAR-2021, the subject experienced eye lids saggy. On 26-MAR-2021, the subject experienced whole face numbness. On 26-MAR-2021, the subject experienced speech issue. Treatment medications (dates unspecified) included: naproxen, and ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on MAR-2021, had not recovered from whole face numbness, and the outcome of headache, all limbs weakness, eye lids saggy, speech issue, visual distortion and dragging feet when walking was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Paraesthesia, Pruritus
Clinical narrative: WHOLE FACE NUMBNESS; SPEECH ISSUE; EYE LIDS SAGGY; VISUAL DISTORTION; ALL LIMBS WEAKNESS; FEVER; HEADACHE; DRAGGING FEET WHEN WALKING; This spontaneous report received from a patient concerned a 48 year old female. The patient's weight was 155 pounds, and height was 158 inches. The patient's concurrent conditions included TODD syndrome -alice in wonderland syndrome, and allergic to clarithromycin. The patient had no history of drug abuse or illicit drug use. The patient was not pregnant at the time of reporting. The patient was non-smoker and non-alcohol user. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022, expiry: UNKNOWN) dose was not reported, administered on 15-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, the subject experienced dragging feet when walking. On 16-MAR-2021, the subject experienced headache. On 17-MAR-2021, the subject experienced visual distortion. On 17-MAR-2021, the subject experienced all limbs weakness. On 17-MAR-2021, the subject experienced fever. On 23-MAR-2021, the subject experienced eye lids saggy. On 26-MAR-2021, the subject experienced whole face numbness. On 26-MAR-2021, the subject experienced speech issue. Treatment medications (dates unspecified) included: naproxen, and ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on MAR-2021, had not recovered from whole face numbness, and the outcome of headache, all limbs weakness, eye lids saggy, speech issue, visual distortion and dragging feet when walking was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dermatochalasis, Dysarthria, Gait disturbance, Headache, Hypoaesthesia
Clinical narrative: WHOLE FACE NUMBNESS; SPEECH ISSUE; EYE LIDS SAGGY; VISUAL DISTORTION; ALL LIMBS WEAKNESS; FEVER; HEADACHE; DRAGGING FEET WHEN WALKING; This spontaneous report received from a patient concerned a 48 year old female. The patient's weight was 155 pounds, and height was 158 inches. The patient's concurrent conditions included TODD syndrome -alice in wonderland syndrome, and allergic to clarithromycin. The patient had no history of drug abuse or illicit drug use. The patient was not pregnant at the time of reporting. The patient was non-smoker and non-alcohol user. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022, expiry: UNKNOWN) dose was not reported, administered on 15-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, the subject experienced dragging feet when walking. On 16-MAR-2021, the subject experienced headache. On 17-MAR-2021, the subject experienced visual distortion. On 17-MAR-2021, the subject experienced all limbs weakness. On 17-MAR-2021, the subject experienced fever. On 23-MAR-2021, the subject experienced eye lids saggy. On 26-MAR-2021, the subject experienced whole face numbness. On 26-MAR-2021, the subject experienced speech issue. Treatment medications (dates unspecified) included: naproxen, and ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on MAR-2021, had not recovered from whole face numbness, and the outcome of headache, all limbs weakness, eye lids saggy, speech issue, visual distortion and dragging feet when walking was not reported. This report was non-serious.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Magnetic resonance imaging, Metamorphopsia, Muscular weakness, Pyrexia
Clinical narrative: WHOLE FACE NUMBNESS; SPEECH ISSUE; EYE LIDS SAGGY; VISUAL DISTORTION; ALL LIMBS WEAKNESS; FEVER; HEADACHE; DRAGGING FEET WHEN WALKING; This spontaneous report received from a patient concerned a 48 year old female. The patient's weight was 155 pounds, and height was 158 inches. The patient's concurrent conditions included TODD syndrome -alice in wonderland syndrome, and allergic to clarithromycin. The patient had no history of drug abuse or illicit drug use. The patient was not pregnant at the time of reporting. The patient was non-smoker and non-alcohol user. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022, expiry: UNKNOWN) dose was not reported, administered on 15-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, the subject experienced dragging feet when walking. On 16-MAR-2021, the subject experienced headache. On 17-MAR-2021, the subject experienced visual distortion. On 17-MAR-2021, the subject experienced all limbs weakness. On 17-MAR-2021, the subject experienced fever. On 23-MAR-2021, the subject experienced eye lids saggy. On 26-MAR-2021, the subject experienced whole face numbness. On 26-MAR-2021, the subject experienced speech issue. Treatment medications (dates unspecified) included: naproxen, and ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on MAR-2021, had not recovered from whole face numbness, and the outcome of headache, all limbs weakness, eye lids saggy, speech issue, visual distortion and dragging feet when walking was not reported. This report was non-serious.
Age: 54.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dizziness, Ear discomfort, Tinnitus, Vertigo
Clinical narrative: Ear pressure; Ringing in ears; Vertigo; Nausea; This is a spontaneous report from a contactable consumer (patient). A 54-year-old male patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: EP7534), intramuscular administered in right arm at a pharmacy or drug store facility on 15Mar2021 13:30 as SINGLE DOSE for COVID-19 immunisation. The patient had no relevant medical history. The patient had no allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination and has not been tested for COVID-19 since the vaccination. Concomitant medications included lamotrigine and other unspecified medication. On 16Mar2021 at 07:00 AM, the patient experienced ear pressure, ringing in ears, vertigo, and nausea. The reporter considered all events as serious (disability). Therapeutic measures were taken as a result for all events which included nasal decongestants from urgent care & primary. The patient had not yet recovered from all events.
Age: 54.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Ear discomfort, Nausea, Tinnitus, Vertigo
Clinical narrative: Ear pressure; Ringing in ears; Vertigo; Nausea; This is a spontaneous report from a contactable consumer (patient). A 54-year-old male patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: EP7534), intramuscular administered in right arm at a pharmacy or drug store facility on 15Mar2021 13:30 as SINGLE DOSE for COVID-19 immunisation. The patient had no relevant medical history. The patient had no allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination and has not been tested for COVID-19 since the vaccination. Concomitant medications included lamotrigine and other unspecified medication. On 16Mar2021 at 07:00 AM, the patient experienced ear pressure, ringing in ears, vertigo, and nausea. The reporter considered all events as serious (disability). Therapeutic measures were taken as a result for all events which included nasal decongestants from urgent care & primary. The patient had not yet recovered from all events.
Age: 54.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dizziness, Hypoacusis, Nausea, Tinnitus
Clinical narrative: Ear pressure; Ringing in ears; Vertigo; Nausea; This is a spontaneous report from a contactable consumer (patient). A 54-year-old male patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: EP7534), intramuscular administered in right arm at a pharmacy or drug store facility on 15Mar2021 13:30 as SINGLE DOSE for COVID-19 immunisation. The patient had no relevant medical history. The patient had no allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination and has not been tested for COVID-19 since the vaccination. Concomitant medications included lamotrigine and other unspecified medication. On 16Mar2021 at 07:00 AM, the patient experienced ear pressure, ringing in ears, vertigo, and nausea. The reporter considered all events as serious (disability). Therapeutic measures were taken as a result for all events which included nasal decongestants from urgent care & primary. The patient had not yet recovered from all events.
Age: 62.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cardiac flutter
Clinical narrative: large flutter in my chest; This is a spontaneous report from a contactable consumer. A 62-year-old female patient received the first dose of bnt162b2 (BNT162B2) lot number: EP6955, via an unspecified route of administration, administered in left arm on 20Mar2021 10:00 as single dose for covid-19 immunisation. Medical history was not reported. Concomitant medications included vitamin D3 and biotin, calcium pantothenate, cyanocobalamin, folic acid, nicotinamide, pyridoxine hydrochloride, riboflavin, thiamine mononitrate (MULTI B "BIOSYM"). On 20Mar2021, 7 hours after Covid vaccine, the patient experienced a large flutter in her chest, lasting about 5 seconds. It happened again after about 5 minutes. No treatment has been received. The outcome of the event was recovered on an unspecified date.  Information about lot/batch number has been requested.
Age: 49.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Atrial fibrillation, Electrocardiogram abnormal, Heart rate increased, Laboratory test normal
Clinical narrative: Atrial Fibrillation / diagnosed with Atrial Fibrillation with RVR; heart rate heightened (topped out at a resting heart rate of over 160 bpm)/ up to 160 (high /bpm)/ continued to have increased; This is a spontaneous report from a contactable consumer (patient). A 49-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Dose 1) via an unspecified route of administration, administered in the left arm on 20Mar2021 18:15 (batch/lot number: ER2613 and expiry date unknown) at 49 years old at a SINGLE DOSE for COVID-19 immunization. The patient was vaccinated at the Hospital. The patient's medical history included obesity from an unknown date and unknown if ongoing. Patient had no previous heart issues and had no known allergies. There were no concomitant medications or other medications in two weeks of vaccination. The patient did not receive other vaccination within 4 weeks prior to the BNT162B2. The patient was not diagnosed with COVID-19 prior to vaccination. The patient has not been tested for COVID-19 since the vaccination. On 21Mar2021, 12:00 am, patient went into atrial fibrillation with a high heart rate up to 160 bpm. It was reported that the heightened heart rate started on evening after the vaccine (on 20Mar2021), it topped out at a resting heart rate of over 160 bpm. Patient went to a primary health care physician, he did EKG (results unknown), then ordered patient to Emergency Room (Hospital name). The patient was diagnosed with Atrial Fibrillation with RVR. The patient was prescribed Apixaban (Eliquis) 5 mg oral tablet, 1 tab 2 times a day and Metoprolol (metoprolol succinate 50 mg extended release) 50 mg 1 cap per day. Patient was also given Diltiazem 10 mg via IV push while at the hospital. It was reported that patient continued to have increased heart rate and have not returned to a normal sinus rhythm as of 23Mar2021. The patient underwent lab tests and procedures which included EKG: unknown result on Mar2021; heart rate: heightened (topped out at a resting heart rate of over 160 bpm ) on 20Mar2021, up to 160 (high /bpm) on 21Mar2021 and heart rate: continued to have increased on 23Mar2021; and sinus rhythm: have not returned to normal  on 23Mar2021. The events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, and patient was hospitalized for one day. The outcome of the events was not recovered.
Age: 49.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Atrial fibrillation, Electrocardiogram, Heart rate, Heart rate increased, Sinus rhythm
Clinical narrative: Atrial Fibrillation / diagnosed with Atrial Fibrillation with RVR; heart rate heightened (topped out at a resting heart rate of over 160 bpm)/ up to 160 (high /bpm)/ continued to have increased; This is a spontaneous report from a contactable consumer (patient). A 49-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Dose 1) via an unspecified route of administration, administered in the left arm on 20Mar2021 18:15 (batch/lot number: ER2613 and expiry date unknown) at 49 years old at a SINGLE DOSE for COVID-19 immunization. The patient was vaccinated at the Hospital. The patient's medical history included obesity from an unknown date and unknown if ongoing. Patient had no previous heart issues and had no known allergies. There were no concomitant medications or other medications in two weeks of vaccination. The patient did not receive other vaccination within 4 weeks prior to the BNT162B2. The patient was not diagnosed with COVID-19 prior to vaccination. The patient has not been tested for COVID-19 since the vaccination. On 21Mar2021, 12:00 am, patient went into atrial fibrillation with a high heart rate up to 160 bpm. It was reported that the heightened heart rate started on evening after the vaccine (on 20Mar2021), it topped out at a resting heart rate of over 160 bpm. Patient went to a primary health care physician, he did EKG (results unknown), then ordered patient to Emergency Room (Hospital name). The patient was diagnosed with Atrial Fibrillation with RVR. The patient was prescribed Apixaban (Eliquis) 5 mg oral tablet, 1 tab 2 times a day and Metoprolol (metoprolol succinate 50 mg extended release) 50 mg 1 cap per day. Patient was also given Diltiazem 10 mg via IV push while at the hospital. It was reported that patient continued to have increased heart rate and have not returned to a normal sinus rhythm as of 23Mar2021. The patient underwent lab tests and procedures which included EKG: unknown result on Mar2021; heart rate: heightened (topped out at a resting heart rate of over 160 bpm ) on 20Mar2021, up to 160 (high /bpm) on 21Mar2021 and heart rate: continued to have increased on 23Mar2021; and sinus rhythm: have not returned to normal  on 23Mar2021. The events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, and patient was hospitalized for one day. The outcome of the events was not recovered.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain upper, Arthralgia, Blood magnesium, Brain natriuretic peptide, Child maltreatment syndrome
Clinical narrative: lightheaded; stomach pain; feeling like fainting; that happened parallel to erratic high blood pressure 199/98.; nausea; Arm pain first day.; fatigue; palpitations; shakes; joints and muscle pain; joints and muscle pain; headache; Chills; night sweats; This is a spontaneous report from a contactable consumer. A 60-years-old male patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Left on 09Mar2021 10:30 (Batch/Lot Number: EN6199) as SINGLE DOSE (at the age of 60 years) for covid-19 immunisation .  Medical history included immune thrombocytopenia from an unknown date and unknown if ongoing , hypertension from an unknown date and unknown if ongoing , drug hypersensitivity from an unknown date and unknown if ongoing , covid-19 from Mar2020 to Sep2020, (COVID 19 Long-Hauler from Mar-Sep2020). Concomitant medications included amlodipine besilate, benazepril hydrochloride (AMLODIPINE BENAZEPRIL); simvastatin (SIMVASTATIN).  The patient previously took aspirin [acetylsalicylic acid] and experienced anaphylactic reaction, zantac and experienced rash and experienced peripheral swelling.  The patient experienced feeling like fainting (medically significant) on 13Mar2021 14:30 with outcome of recovering , that happened parallel to erratic high blood pressure 199/98 on 13Mar2021 14:30 with outcome of recovering , palpitations  on Mar2021 with outcome of recovering , lightheaded on 13Mar2021 14:30 with outcome of recovering , stomach pain on 13Mar2021 14:30 with outcome of recovering , shakes on Mar2021 with outcome of recovering , joints and muscle pain, headache on Mar2021 with outcome of recovering , chills on Mar2021 with outcome of recovering , night sweats on Mar2021 with outcome of recovering , nausea on 13Mar2021 14:30 with outcome of recovering , arm pain first day on 09Mar2021 with outcome of recovering , fatigue on Mar2021 with outcome of recovering.  The patient underwent lab tests and procedures which included blood pressure measurement: 120's-30's/70's, blood pressure measurement: 199/98   on 13Mar2021, platelet count: 99, sars-cov-2 test: Several negative tests on unspecified date.  The patient went to Urgent Care twice. The patient took no other vaccine in four weeks and the patient was not COVID tested post vaccination.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chills, Differential white blood cell count, Dizziness, Fatigue, Fibrin D dimer
Clinical narrative: lightheaded; stomach pain; feeling like fainting; that happened parallel to erratic high blood pressure 199/98.; nausea; Arm pain first day.; fatigue; palpitations; shakes; joints and muscle pain; joints and muscle pain; headache; Chills; night sweats; This is a spontaneous report from a contactable consumer. A 60-years-old male patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Left on 09Mar2021 10:30 (Batch/Lot Number: EN6199) as SINGLE DOSE (at the age of 60 years) for covid-19 immunisation .  Medical history included immune thrombocytopenia from an unknown date and unknown if ongoing , hypertension from an unknown date and unknown if ongoing , drug hypersensitivity from an unknown date and unknown if ongoing , covid-19 from Mar2020 to Sep2020, (COVID 19 Long-Hauler from Mar-Sep2020). Concomitant medications included amlodipine besilate, benazepril hydrochloride (AMLODIPINE BENAZEPRIL); simvastatin (SIMVASTATIN).  The patient previously took aspirin [acetylsalicylic acid] and experienced anaphylactic reaction, zantac and experienced rash and experienced peripheral swelling.  The patient experienced feeling like fainting (medically significant) on 13Mar2021 14:30 with outcome of recovering , that happened parallel to erratic high blood pressure 199/98 on 13Mar2021 14:30 with outcome of recovering , palpitations  on Mar2021 with outcome of recovering , lightheaded on 13Mar2021 14:30 with outcome of recovering , stomach pain on 13Mar2021 14:30 with outcome of recovering , shakes on Mar2021 with outcome of recovering , joints and muscle pain, headache on Mar2021 with outcome of recovering , chills on Mar2021 with outcome of recovering , night sweats on Mar2021 with outcome of recovering , nausea on 13Mar2021 14:30 with outcome of recovering , arm pain first day on 09Mar2021 with outcome of recovering , fatigue on Mar2021 with outcome of recovering.  The patient underwent lab tests and procedures which included blood pressure measurement: 120's-30's/70's, blood pressure measurement: 199/98   on 13Mar2021, platelet count: 99, sars-cov-2 test: Several negative tests on unspecified date.  The patient went to Urgent Care twice. The patient took no other vaccine in four weeks and the patient was not COVID tested post vaccination.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Full blood count, Headache, Hypertension, Metabolic function test, Myalgia
Clinical narrative: lightheaded; stomach pain; feeling like fainting; that happened parallel to erratic high blood pressure 199/98.; nausea; Arm pain first day.; fatigue; palpitations; shakes; joints and muscle pain; joints and muscle pain; headache; Chills; night sweats; This is a spontaneous report from a contactable consumer. A 60-years-old male patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Left on 09Mar2021 10:30 (Batch/Lot Number: EN6199) as SINGLE DOSE (at the age of 60 years) for covid-19 immunisation .  Medical history included immune thrombocytopenia from an unknown date and unknown if ongoing , hypertension from an unknown date and unknown if ongoing , drug hypersensitivity from an unknown date and unknown if ongoing , covid-19 from Mar2020 to Sep2020, (COVID 19 Long-Hauler from Mar-Sep2020). Concomitant medications included amlodipine besilate, benazepril hydrochloride (AMLODIPINE BENAZEPRIL); simvastatin (SIMVASTATIN).  The patient previously took aspirin [acetylsalicylic acid] and experienced anaphylactic reaction, zantac and experienced rash and experienced peripheral swelling.  The patient experienced feeling like fainting (medically significant) on 13Mar2021 14:30 with outcome of recovering , that happened parallel to erratic high blood pressure 199/98 on 13Mar2021 14:30 with outcome of recovering , palpitations  on Mar2021 with outcome of recovering , lightheaded on 13Mar2021 14:30 with outcome of recovering , stomach pain on 13Mar2021 14:30 with outcome of recovering , shakes on Mar2021 with outcome of recovering , joints and muscle pain, headache on Mar2021 with outcome of recovering , chills on Mar2021 with outcome of recovering , night sweats on Mar2021 with outcome of recovering , nausea on 13Mar2021 14:30 with outcome of recovering , arm pain first day on 09Mar2021 with outcome of recovering , fatigue on Mar2021 with outcome of recovering.  The patient underwent lab tests and procedures which included blood pressure measurement: 120's-30's/70's, blood pressure measurement: 199/98   on 13Mar2021, platelet count: 99, sars-cov-2 test: Several negative tests on unspecified date.  The patient went to Urgent Care twice. The patient took no other vaccine in four weeks and the patient was not COVID tested post vaccination.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Nausea, Night sweats, Pain in extremity, Palpitations, Platelet count
Clinical narrative: lightheaded; stomach pain; feeling like fainting; that happened parallel to erratic high blood pressure 199/98.; nausea; Arm pain first day.; fatigue; palpitations; shakes; joints and muscle pain; joints and muscle pain; headache; Chills; night sweats; This is a spontaneous report from a contactable consumer. A 60-years-old male patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Left on 09Mar2021 10:30 (Batch/Lot Number: EN6199) as SINGLE DOSE (at the age of 60 years) for covid-19 immunisation .  Medical history included immune thrombocytopenia from an unknown date and unknown if ongoing , hypertension from an unknown date and unknown if ongoing , drug hypersensitivity from an unknown date and unknown if ongoing , covid-19 from Mar2020 to Sep2020, (COVID 19 Long-Hauler from Mar-Sep2020). Concomitant medications included amlodipine besilate, benazepril hydrochloride (AMLODIPINE BENAZEPRIL); simvastatin (SIMVASTATIN).  The patient previously took aspirin [acetylsalicylic acid] and experienced anaphylactic reaction, zantac and experienced rash and experienced peripheral swelling.  The patient experienced feeling like fainting (medically significant) on 13Mar2021 14:30 with outcome of recovering , that happened parallel to erratic high blood pressure 199/98 on 13Mar2021 14:30 with outcome of recovering , palpitations  on Mar2021 with outcome of recovering , lightheaded on 13Mar2021 14:30 with outcome of recovering , stomach pain on 13Mar2021 14:30 with outcome of recovering , shakes on Mar2021 with outcome of recovering , joints and muscle pain, headache on Mar2021 with outcome of recovering , chills on Mar2021 with outcome of recovering , night sweats on Mar2021 with outcome of recovering , nausea on 13Mar2021 14:30 with outcome of recovering , arm pain first day on 09Mar2021 with outcome of recovering , fatigue on Mar2021 with outcome of recovering.  The patient underwent lab tests and procedures which included blood pressure measurement: 120's-30's/70's, blood pressure measurement: 199/98   on 13Mar2021, platelet count: 99, sars-cov-2 test: Several negative tests on unspecified date.  The patient went to Urgent Care twice. The patient took no other vaccine in four weeks and the patient was not COVID tested post vaccination.
Age: 60.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Troponin
Clinical narrative: lightheaded; stomach pain; feeling like fainting; that happened parallel to erratic high blood pressure 199/98.; nausea; Arm pain first day.; fatigue; palpitations; shakes; joints and muscle pain; joints and muscle pain; headache; Chills; night sweats; This is a spontaneous report from a contactable consumer. A 60-years-old male patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Left on 09Mar2021 10:30 (Batch/Lot Number: EN6199) as SINGLE DOSE (at the age of 60 years) for covid-19 immunisation .  Medical history included immune thrombocytopenia from an unknown date and unknown if ongoing , hypertension from an unknown date and unknown if ongoing , drug hypersensitivity from an unknown date and unknown if ongoing , covid-19 from Mar2020 to Sep2020, (COVID 19 Long-Hauler from Mar-Sep2020). Concomitant medications included amlodipine besilate, benazepril hydrochloride (AMLODIPINE BENAZEPRIL); simvastatin (SIMVASTATIN).  The patient previously took aspirin [acetylsalicylic acid] and experienced anaphylactic reaction, zantac and experienced rash and experienced peripheral swelling.  The patient experienced feeling like fainting (medically significant) on 13Mar2021 14:30 with outcome of recovering , that happened parallel to erratic high blood pressure 199/98 on 13Mar2021 14:30 with outcome of recovering , palpitations  on Mar2021 with outcome of recovering , lightheaded on 13Mar2021 14:30 with outcome of recovering , stomach pain on 13Mar2021 14:30 with outcome of recovering , shakes on Mar2021 with outcome of recovering , joints and muscle pain, headache on Mar2021 with outcome of recovering , chills on Mar2021 with outcome of recovering , night sweats on Mar2021 with outcome of recovering , nausea on 13Mar2021 14:30 with outcome of recovering , arm pain first day on 09Mar2021 with outcome of recovering , fatigue on Mar2021 with outcome of recovering.  The patient underwent lab tests and procedures which included blood pressure measurement: 120's-30's/70's, blood pressure measurement: 199/98   on 13Mar2021, platelet count: 99, sars-cov-2 test: Several negative tests on unspecified date.  The patient went to Urgent Care twice. The patient took no other vaccine in four weeks and the patient was not COVID tested post vaccination.